REAL-WORLD OUTCOMES IN PATIENTS WITH PENILE SQUAMOUS CELL CARCINOMA (PSCC) RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICI)

被引：2

作者：

Zhuang, Tony ^{[1
]}

Goyal, Subir ^{[1
]}

Brown, Jacqueline ^{[1
]}

Carthon, Bradley ^{[1
]}

Kucuk, Omer ^{[1
]}

McClintock, Greta ^{[1
]}

Yantorni, Lauren ^{[1
]}

Bilen, Mehmet ^{[1
]}

Master, Viraj ^{[1
]}

Nazha, Bassel ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Atlanta, GA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0478

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

478

引用

页码：A498 / A499

页数：2

共 50 条

[31] Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors
Leddon, Jennifer L.
Chirra, Martina
Frankart, Andrew J.
Agrawal, Arushi
Roof, Logan
Trotier, Danny
Shaikh, Hira
Stone, Timothy
Jandarov, Roman
Takiar, Vinita
Wise-Draper, Trisha M.
LARYNGOSCOPE, 2021, 131 (07): : E2413 - E2419
[32] Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario
Iacono, D.
Vitale, M. G.
Cortiula, F.
Cinausero, M.
Tullio, A.
Valent, F.
Macerelli, M.
Follador, A.
Vogrig, A.
Minisini, A. M.
Puglisi, F.
Fasola, G.
ANNALS OF ONCOLOGY, 2018, 29
[33] REAL-WORLD STUDY OF METASTATIC MERKEL CELL CARCINOMA PATIENTS RECEIVING CHECKPOINT INHIBITORS (CPIS) VS. CHEMOTHERAPY TREATMENTS
Zheng, Y.
Kim, R.
Yu, T.
Dreyfus, J.
Gayle, J. A.
Wassel, C. L.
Phatak, H.
VALUE IN HEALTH, 2019, 22 : S117 - S117
[34] Real-world data in the era of immune checkpoint inhibitors
Narita, Yukiya
ANNALS OF ONCOLOGY, 2021, 32 : S250 - S250
[35] Myositis with immune checkpoint inhibitors in a real-world setting
Reactions Weekly, 2020, 1794 (1) : 11 - 11
[36] Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).
Alfieri, Salvatore
Ferrara, Roberto
Calareso, Giuseppina
Cavalieri, Stefano
Platini, Francesca
Mancinelli, Moela
Resteghini, Carlo
Orlandi, Ester
Iacovelli, Nicola Alessandro
Ferella, Letizia
Piazza, Cesare
Apollonio, Giulia
Galbiati, Donata
Bossi, Paolo
Bergamini, Cristiana
Locati, Laura Deborah
Licitra, Lisa F.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[37] Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
Dudnik, Elizabeth
Kareff, Samuel
Moskovitz, Mor
Kim, Chul
Liu, Stephen, V
Lobachov, Anastasiya
Gottfried, Teodor
Urban, Damien
Zer, Alona
Rotem, Ofer
Onn, Amir
Wollner, Mira
Bar, Jair
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
[38] Real-world validation of the Khorana risk score in gastric cancer patients receiving immune checkpoint inhibitors.
Song, Junmin
Li, Wing Fai
Yim, Chaeseong
Gong, Changlin
Chang, Yu-Cheng
Chang, Yu
Ahn, Jaeun
Chi, Kuan-Yu
Fahimuddin, Muhammad
Chiang, Cho Han
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 363 - 363
[39] Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).
Khozin, Sean
Walker, Mark S.
Jun, Monika
Chen, Li
Stepanski, Edward
Rubinstein, Wendy S.
Komatsoulis, George Anthony
Roberts, Jeremy
Zhi, Jizu
Miller, Robert S.
Fukushima, Ryan
Lau, Denise
Hyde, Brigham
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[40] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
Chen, Kang
Wei, Wei
Liu, Lei
Deng, Zhu-Jian
Li, Le
Liang, Xiu-Mei
Guo, Ping-Ping
Qi, Lu-Nan
Zhang, Zhi-Ming
Gong, Wen-Feng
Huang, Shan
Yuan, Wei-Ping
Ma, Liang
Xiang, Bang-De
Li, Le-Qun
Zhong, Jian-Hong
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074

← 1 2 3 4 5 →